Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRALYSE: Low-dose prolonged infusion vs standard Alteplase in acute ischemic stroke
NCT00132509Phase 2Terminated
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2001
- Primary completion
- Aug 2008
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tissue-plasminogen activator in ischemic stroke, sponsored by Hospices Civils de Lyon. Primary endpoint: Modified Rankin Score at 90 days. Started Sep 2001; status: terminated.
02
Drugs
tissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00132509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132509.